etoposide has been researched along with everolimus in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Marik, PE; Vahid, B | 1 |
| Arcaro, A; Dhillon, T; Lane, HA; Lemoine, NR; Marinov, M; Mauri, FA; Pardo, OE; Seckl, MJ; Tan, LT; Zangemeister-Wittke, U; Ziogas, A | 1 |
| He, XX; Huang, JJ; Huang, Y; Li, ZM; Lin, TY; Tian, Y; Xiao, J | 1 |
| Couvelard, A; de Gramont, A; Faivre, S; Hammel, P; Neuzillet, C; Raymond, E; Serova, M; Tijeras-Raballand, A | 1 |
| Beck, JT; Besse, B; Camidge, DR; Dimitrijevic, S; Heist, RS; Johnson, BE; Miller, N; Mulatero, C; Papadmitrakopoulou, VA; Petrovic, K; Pylvaenaeinen, I; Schmid, P; Urva, S | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Shimizu, S; Takahashi, H; Ueno, H | 1 |
| Wolin, EM | 1 |
| Belada, D; Bermudez Silva, CD; Bouabdallah, K; Cavalli, F; Costa, LJ; Fan, J; Fayad, L; Hino, M; Ikeda, T; Kattan, JG; Kim, WS; Kuruvilla, J; Larouche, JF; Louveau, AL; Mayer, J; Ogura, M; Ozcan, M; Rigacci, L; Shi, Y; Tobinai, K; Vanazzi, A; Voi, M; Witzig, TE; Wu, C; Zhu, J | 1 |
| Gao, TX; Huang, JJ; Jiang, WQ; Li, ZM; Sun, P; Sun, XQ; Wang, CQ; Wang, Y; Wu, K | 1 |
| Halfdanarson, TR; Leventakos, K; Molina, JR; Uprety, D | 1 |
6 review(s) available for etoposide and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pulmonary complications of novel antineoplastic agents for solid tumors.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Everolimus; Gemcitabine; Humans; Lung; Lung Diseases; Mitoxantrone; Neoplasms; Pneumonia; Pyrimidines; Risk Factors; Sirolimus; Teniposide; Trastuzumab | 2008 |
Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Medical Oncology; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Administration Schedule; Etoposide; Everolimus; Humans; Irinotecan; Pancreatic Neoplasms | 2015 |
Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cisplatin; Disease Management; Etoposide; Everolimus; Humans; Lung Neoplasms; Neuroendocrine Tumors; Octreotide; Peptides, Cyclic; Pneumonectomy; Small Cell Lung Carcinoma; Somatostatin | 2017 |
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Capecitabine; Carcinoid Tumor; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Everolimus; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lymph Node Excision; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pneumonectomy; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Temozolomide; Watchful Waiting | 2020 |
2 trial(s) available for etoposide and everolimus
| Article | Year |
|---|---|
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Everolimus; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Sirolimus; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Everolimus; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Rituximab; Vincristine; Young Adult | 2018 |
4 other study(ies) available for etoposide and everolimus
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
Topics: Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Etoposide; Everolimus; Humans; Lung Neoplasms; Mice; Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sirolimus; Stem Cell Factor; TOR Serine-Threonine Kinases | 2009 |
Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Everolimus; Humans; Jurkat Cells; Lymphoma, T-Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazines; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Vincristine | 2012 |
Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non-Hodgkin lymphoma.
Topics: Administration, Metronomic; Antineoplastic Combined Chemotherapy Protocols; Autophagy-Related Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Etoposide; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Survival Analysis; Treatment Outcome | 2019 |